Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Rafael Biotechnology Company Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is currently limited to 1 distinct examiner and 1 distinct art unit. PARKIN, JEFFREY S is the busiest examiner, with 1 busiest examiner pending office action. The company's current matter before the patent office is concentrated under these specific parameters. With a single official and a single unit, the prosecution process is highly centralized.
The outcome of the 1 pending office action will depend on the specific feedback from PARKIN, JEFFREY S, who manages the 1 busiest examiner pending action. This workload represents the entirety of the company's current patenting activity in the Biotechnology & Pharmaceuticals field. Because there is only 1 distinct examiner, the applicant can focus its efforts on a single relationship. The concentration in 1 distinct art unit suggests a specific technical focus for the company's current filings. Practitioners should prioritize this interaction as the key to the company's immediate intellectual property goals. This concentration allows for a highly tailored approach to the specific requirements of the sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARKIN, JEFFREY S | 1 | 63.7% | +21.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18197987 | CRISPR-Cas13 System, Kit and Method for Detecting SARS-CoV-2 | PARKIN, JEFFREY S | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18197987 | CRISPR-Cas13 System, Kit and Method for Detecting SARS-CoV-2 | PARKIN, JEFFREY S | 1671 | §103 | Non-Final OA | — | Pending | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial